Collaboration agreements for oncology candidates were signed between several major pharmaceutical companies.
1 report, 1 independent
Updated Aug 5
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Collaboration agreements for oncology candidates were signed between several major pharmaceutical companies.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- A partnership involving Recursion Pharmaceuticals, Sanofi, Roche, Merck, and Relay Therapeutics diversifies pipelines across oncology and immunology, leveraging AI-driven platforms.Sub-event
Sanofi, Roche, and others signed new collaboration agreements for oncology candidates.1 source
Keep exploring
Part of
Major pharmaceutical companies including Sanofi, Regeneron, Roche, Eli Lilly, Biogen, and Gilead are maintaining alliances and competing across key therapeutic areas like ophthalmology, immunology, and oncology.Also in this story
- Skyclarys announced its international expansion into Brazil and the U.K. on July 22, 2025.
- Organon acquired U.S. rights to TOFIDENCE from Biogen and laid off employees at its Jersey City headquarters.
- Biogen enhances patient outcomes through key drugs and therapies, while NIH studies reveal global incidence of ALS and CDC projects rising patient numbers in the U.S.
- Sales of products including Vivitrol, Aristada, and Lybalvi increased due to strong market demand and new prescriptions.
The entities involved
-
Hoffmann-La Roche
Swiss healthcare company
-
Sanofi
company in Milan, Italy
Nothing else this week.
Related events
Coverage
Newest first; wire copies grouped- ZacksRecursion Pharmaceuticals to Report Q2 Earnings: What's in the Cards? Recursion Pharmaceuticals RXRX, a TechBio company that decodes biology and chemistry to industrialize drug discovery, is expected